ALOX12B is altered in 1.34% of all cancers with colon adenocarcinoma, lung adenocarcinoma, prostate adenocarcinoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in ALOX12B are ALOX12B Loss (0.30%), ALOX12B Amplification (0.08%), ALOX12B P531L (0.02%), ALOX12B V435I (0.01%), and ALOX12B I239V (0.04%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.